logo

IOBT

IO BiotechยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

IOBT Profile

Io Biotech, Inc.

A biotechnology company that develops and commercializes immunotherapies for cancer treatment

Pharmaceutical
05/25/2021
11/05/2021
NASDAQ Stock Exchange
80
12-31
Common stock
Ole Maales Vej 3, DK-2200 Copenhagen N, Denmark
--
IO Biotech, Inc., was incorporated in Delaware on May 25, 2021. The company is a clinical-stage biopharmaceutical company developing novel, immune-modulated cancer therapies based on its T-win technology platform. The company's product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. The company believes that this represents a shift in cancer management, and the company's product candidates have the potential to become the cornerstone of a variety of solid tumor treatment options. The company's T-win platform is a new approach to cancer immunotherapy designed to activate naturally occurring T cells to drive targeted immunosuppressive mechanisms.